Author Topic: (AAN abst.) Impact of Tysabri switch to moderate vs. high-efficacy DMT  (Read 7 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8134
  • MS diagnosed 1980
  • Location: Pacific Northwest
Abstract of a paper presented at the annual AAN conference (Philadelphia, May 4-10, 2019) by researchers at the Cleveland Clinic entitled "Early Impact of Natalizumab Switch to Moderate Versus High Efficacy Disease Modifying Therapy in Clinical Practice":


http://indexsmart.mirasmart.com/AAN2019/PDFfiles/AAN2019-000892.pdf
MS Speaks--online for 12 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
50 Views
Last post March 11, 2017, 07:08:23 am
by agate
0 Replies
31 Views
Last post October 16, 2018, 02:57:48 pm
by agate
0 Replies
32 Views
Last post November 02, 2018, 07:30:04 am
by agate
0 Replies
5 Views
Last post April 17, 2019, 02:42:04 pm
by agate
0 Replies
5 Views
Last post June 15, 2019, 03:58:40 pm
by agate